OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Shares Outstanding

Last Annual Value

13.52M

3-Year CAGR

%

5-Year CAGR

40%

10-Year CAGR

18%

OT

OnKure Therapeutics, Inc. Competitors Analysis of shares-outstanding

OKUR · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.52M
0.4%49.4%N/A 
46.38M
14.4%12.6%41.5%
7.32M
-53.5%-32.6%-5.6%
9.88M
-26.5%-24.3%N/A
1.99M
10.3%8.0%26.9%
83.59M
249.1%191.0%N/A
30.07M
4.2%7.9%34.0%
4.90M
1.8%11.7%21.5%
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47